ライフサイエンスコーパス: Ebola

1 West Africa that were recently devastated by Ebola.

2 r modulators (SERMs), possess selective anti-Ebola activities.

3 line hydrochloride was reported to have anti-Ebola activity in vitro alone and in combination with ot

4 drug which had existing data reporting anti-Ebola activity.

5 o recent acute epidemics, including the 2014 Ebola and 2015 Zika epidemics.

6 ty of viruses circulating in bats, including Ebola and influenza A-like viruses.

7 ncluding significant human pathogens such as Ebola and influenza viruses.

8 pathogens, such as anthrax, bubonic plague, Ebola and Marburg fever.

9 Ebola and Marburg viruses are filoviruses: filamentous,

10 ted specific areas to care for patients with Ebola and other highly infectious diseases.

11 ection of humans by lethal pathogens such as Ebola and other related viruses has not been properly ad

12 The recent Ebola and Zika epidemics demonstrate the need for the co

13 ge is difficult, yet, as shown by the recent Ebola and Zika epidemics, effective and timely responses

14 ction contributes little to herd immunity in Ebola, and even if infectious, would account for few tra

15 Because viral pandemics, such as influenza, Ebola, and Zika, are becoming more common, and pregnant

16 the known hotspot residues of different anti-Ebola antibodies that would impact antibody-epitope inte

17 This Ebola vaccine candidate elicited anti-Ebola antibody responses.

18 semen informs the care of male survivors of Ebola, as well as recommendations for public health.

19 The Cepheid Xpert Ebola assay for EBOV RNA detection was validated for who

20 The Cepheid Xpert Ebola assay is accurate and precise for detecting EBOV i

21 , cluster-randomised ring vaccination trial (Ebola ca Suffit!) in the communities of Conakry and eigh

22 Sierra Leone were most heavily affected, but Ebola cases were exported to several other African and E

23 Ebola cDNA was amplified by rolling circle amplification

24 onoclonal antibody cocktails that target the Ebola coat glycoprotein (GP).

25 does prevent splashing, which is critical in Ebola contexts.

26 The Ebola crisis occurred in West-Africa highlights the urge

27 This work addresses the design of an Ebola diagnostic test involving a simple, rapid, specifi

28 as a critical target for development of anti-Ebola drugs.

29 t has been shown to be the primary source of Ebola (EBOV) transmission.

30 Marburg (MARV) and Ebola (EBOV) viruses are zoonotic pathogens that cause s

31 umulation, which in turn led to blocking the Ebola entry.

32 mong returned responders to the West African Ebola epidemic 2014-2016.

33 ears to have ceased in 2016, the West Africa Ebola epidemic has profoundly influenced discussions and

34 The diagnostic response to the 2014-15 Ebola epidemic, although ultimately effective, was slow

35 es, particularly the Syrian conflict and the Ebola epidemic, I recommend four sets of actions that wo

36 Major challenges for managing future Ebola epidemics include establishment of early and aggre

37 that multiple viruses, including dengue and Ebola, exploit AAK1 and GAK during entry and infectious

38 dependently identified a polymorphism in the Ebola glycoprotein (I544) that enhanced virus entry, but

39 point-of-care technology is evaluated using Ebola glycoprotein suspended in diluted PBS buffer, huma

40 Animals generated their own Ebola glycoprotein-specific IgG responses 9-15 days afte

41 s highly sensitive and specific detection of Ebola glycoprotein.

42 irus-like particles both encoding a modified Ebola glycoprotein.

43 n EBOV IgG capture assay that detects IgG to Ebola glycoprotein.

44 ver years, were examined for the presence of Ebola-GP specific IgG subclasses, and for their binding

45 West Africa epidemic of Ebola virus disease (Ebola) had resulted in a total of 28,646 cases, 11,323 o

46 collected data on 1054 children admitted to Ebola Holding Units in Sierra Leone and describe outcome

47 13 months after the negative PCR result for Ebola in the blood.

48 An ophthalmologic follow-up for Ebola-infected patients should start, if possible, durin

49 utility as a post-exposure prophylactic for Ebola infection and provides a low cost, scalable altern

50 In murine models of dengue and Ebola infection, sunitinib/erlotinib combination protect

51 uced cholesterol accumulation also inhibited Ebola infection.

52 mechanism as to their inhibitory effects on Ebola infection.

53 es with diverse natural histories, including Ebola, influenza A, and severe acute respiratory syndrom

54 ging diseases such as malaria, tuberculosis, Ebola, influenza, AIDS, and cancer.

55 ce of T544I during serial passage of various Ebola Makona isolates on Vero E6 cells.

56 Our study clarified the specific anti-Ebola mechanism of SERMs, even the cationic amphiphilic

57 By coding and running 37 published Ebola models with five candidate interventions, we found

58 s but are dangerous zoonotic pathogens, like Ebola or rabies virus.

59 We look at lessons learned from the Ebola outbreak and propose specific solutions to improve

60 e range in caseload projections for the 2014 Ebola outbreak caused great concern and debate about the

61 In response to the Ebola outbreak in 2014, many hospitals designated specif

62 ission, and reporting delays during the 2014 Ebola outbreak in West Africa highlighted the need for a

63 es were a documented concern during the 2013 Ebola outbreak in West Africa.

64 The unprecedented scale of the Ebola outbreak in Western Africa (2014-2015) has prompte

65 ly applied to data that describes a regional Ebola outbreak in Western Africa (2014-2015).

66 The Ebola outbreak of 2013-2016 severely affected West Afric

67 ur methods to data collected during the 2014 Ebola outbreak, identifying several likely routes of tra

68 In the 2014 West African Ebola outbreak, international organizations provided con

69 ase transmission from uncontrolled spills in Ebola outbreaks.

70 Ebola padlock probes were designed to detect a specific

71 administered under compassionate use to two Ebola patients, both of whom survived, and is currently

72 antiviral activity of these compounds in an Ebola pseudotyped infection model was in the low micromo

73 Ebola response teams and laboratory workers were unaware

74 ludes that China's Belt and Road Initiative, Ebola response, development assistance for health, and n

75 The Ebola RNA is hybridized with sequence specific capture a

76 most fatal, and longest lasting epidemic in Ebola's history, presented an enormous international pub

77 hallenge, but it also provided insights into Ebola's pathogenesis and natural history, clinical expre

78 ene sequence present in the five most common Ebola species.

79 glycoproteins (GPs) and potently neutralizes Ebola, Sudan, Bundibugyo, and Reston viruses.

80 test organisms were Escherichia coli and the Ebola surrogate Phi6.

81 cs and the antigen specificity of T cells in Ebola survivors are scarce, and our understanding of EVD

82 The large number of Ebola survivors has highlighted the frequency of persist

83 ence of Ebola virus RNA in the semen of male Ebola survivors participating in the Postebogui study in

84 subclass correlated in the studied group of Ebola survivors.

85 y-based protocol to improve cooperation with Ebola testing as well as contact tracing, quarantining,

86 lopment ahead of the outbreak, point-of-care Ebola tests supporting a less costly and more mobile res

87 3 (16%) as having had incidents with risk of Ebola transmission, including five intermediate-risk and

88 ures prominently in first-hand narratives of Ebola transmission, its dynamics have not been systemati

89 ed ocular disorders after discharge from the Ebola treatment center.

90 within the 2 months after discharge from the Ebola treatment center.

91 apture assay among survivors from Kerry Town Ebola Treatment Centre and controls from communities una

92 al, Forecariah) following discharge from any Ebola treatment centre in Guinea.

93 iewed for demographic information, length of Ebola treatment unit (ETU) stay, visual acuity (VA), and

94 ne, at various times after discharge from an Ebola treatment unit (ETU), in two phases (100 participa

95 and rapid testing was not available in many Ebola Treatment Units (ETUs), guidelines recommended emp

96 irmed EVD were enrolled retrospectively in 5 Ebola treatment units in Liberia and Sierra Leone in 201

97 y of supportive care to patients admitted to Ebola treatment units.

98 eatment in remote, resource-poor areas where Ebola typically reemerges.

99 rvations are important for further informing Ebola vaccine and therapeutic development.

100 This Ebola vaccine candidate elicited anti-Ebola antibody res

101 nder expanded access, the first time that an Ebola vaccine has been used in an outbreak setting outsi

102 regnant women with confirmed EVD had similar Ebola viral loads on presentation to nonpregnant women,

103 Ebola viral protein 30 (eVP30) plays a critical role in

104 classified in a genus distinct from that of Ebola virus (EBOV) (genera Marburgvirus and Ebolavirus,

105 Ebola virus (EBOV) and Reston virus (RESTV) are members

106 Both Ebola virus (EBOV) and Reston virus (RESTV) cause diseas

107 Immune responses in survivors of Ebola virus (EBOV) and Sudan virus (SUDV) infections hav

108 Ebola virus (EBOV) causes severe systemic disease in hum

109 A 9-month-old infant died from Ebola virus (EBOV) disease with unknown epidemiological

110 The recent Ebola virus (EBOV) epidemic in West Africa demonstrates

111 The Ebola virus (EBOV) genome encodes a partly conserved 40-

112 on of a safe and efficacious vaccine against Ebola virus (EBOV) has proven elusive so far, but variou

113 Ebola virus (EBOV) infection is characterized by sporadi

114 of EVD survival in which the patient cleared Ebola virus (EBOV) infection without experimental drugs

115 rposes-proved disappointing in tests against Ebola virus (EBOV) infection, more recently, specific mo

116 s have shown promise for treatment of lethal Ebola virus (EBOV) infections, but their species-specifi

117 tion of EBOV VP40-mediated egress.IMPORTANCE Ebola virus (EBOV) is a high-priority, emerging human pa

118 Ebola virus (EBOV) is a member of the Filoviridae family

119 Ebola virus (EBOV) is an enveloped negative-sense RNA vi

120 The recent Ebola virus (EBOV) outbreak in West Africa was the large

121 The recent 2014-2016 Ebola virus (EBOV) outbreak prompted increased efforts t

122 rn, as exemplified by the recent devastating Ebola virus (EBOV) outbreak.

123 Despite sporadic outbreaks of Ebola virus (EBOV) over the last 4 decades and the recen

124 Ebola virus (EBOV) persistence in asymptomatic humans an

125 Ebola virus (EBOV) poses a significant threat to human h

126 Recent studies have suggested that Ebola virus (EBOV) ribonucleic acid (RNA) potentially pr

127 Ebola virus (EBOV) RNA persistence in semen, reported se

128 Ebola virus (EBOV) survivors are affected by a variety o

129 re on diagnostic test results and infectious Ebola virus (EBOV) titers.

130 The Ebola virus (EBOV) variant Makona (which emerged in 2013

131 The interaction of Ebola virus (EBOV) VP24 protein with host karyopherin al

132 rabies virus (RABV) vectored vaccine against Ebola virus (EBOV), a major threat to wild chimpanzees a

133 Ebola virus (EBOV), a member of the Filoviridae family,

134 ers are at particular risk of infection with Ebola virus (EBOV).

135 against lethal challenge with mouse-adapted Ebola virus (ma-EBOV) in a dose-dependent manner.

136 r the species Zaire ebolavirusIMPORTANCE The Ebola virus (Zaire) species is the most lethal species o

137 Before vaccination, Zaire Ebola virus (ZEBOV)-glycoprotein (GP)-specific and ZEBOV

138 essing the glycoprotein of a Zaire strain of Ebola virus (ZEBOV).

139 To address the potential that anti-Ebola virus activity was overlooked, type I and type II

140 s including crucial mutations in VP24 enable Ebola virus adaptation to new hosts.

141 ified 33 different mutations associated with Ebola virus adaptation to rodents in the proteins GP, NP

142 ach to analyze the mutations associated with Ebola virus adaptation to rodents to elucidate the deter

143 iviral potential, including activity against Ebola virus and bat influenza A-like virus, and we descr

144 ntrast to tetrameric predictions for VP35 of Ebola virus and to known structures of homologous protei

145 sistor method for real-time detection of the Ebola virus antigen.

146 t part in reducing community transmission of Ebola virus by providing more immediate protection than

147 a venous blood specimen tested negative for Ebola virus by quantitative reverse-transcription polyme

148 Ebola virus causes devastating hemorrhagic fever outbrea

149 ndicated that this mutation was not found in Ebola virus clinical samples.

150 Asymptomatic infection with Ebola virus could contribute to population immunity, red

151 We show here that the Ebola virus delta peptide, a conserved nonstructural pro

152 r (SPM) has been developed and evaluated for Ebola virus detection.

153 d of March 2016, the West Africa epidemic of Ebola virus disease (Ebola) had resulted in a total of 2

154 es of 697/1054 children testing negative for Ebola virus disease (EVD) and accompanying caregivers.

155 The 2014-15 Ebola virus disease (EVD) epidemic strained health syste

156 The west Africa Ebola virus disease (EVD) epidemic was extraordinary in

157 ata are lacking on pregnancy outcomes during Ebola virus disease (EVD) epidemics.

158 rs from the 2013-16 west African outbreak of Ebola virus disease (EVD) has raised several new issues:

159 he clinical and virologic characteristics of Ebola virus disease (EVD) in children have not been thor

160 isual impairment in a cohort of survivors of Ebola virus disease (EVD) in Monrovia, Liberia.

161 the semen of a large number of survivors of Ebola virus disease (EVD) in Western Africa may contribu

162 Ebola virus disease (EVD) is a contagious, severe and of

163 Ebola virus disease (EVD) is a serious illness with mort

164 The pathogenesis of human Ebola virus disease (EVD) is complex.

165 ore, rapid, accurate, and early diagnosis of Ebola virus disease (EVD) is critical to public health c

166 The worst Ebola virus disease (EVD) outbreak in history has result

167 , 2016, all known transmission chains of the Ebola virus disease (EVD) outbreak in west Africa had be

168 The West African Ebola virus disease (EVD) outbreak was the largest EVD o

169 The unprecedented 2014 epidemic of Ebola virus disease (EVD) prompted an international resp

170 EBOV) persistence in asymptomatic humans and Ebola virus disease (EVD) sequelae have emerged as signi

171 e safety and efficacy of vaccines to prevent Ebola virus disease (EVD) were unknown when the incidenc

172 infectious it could explain re-emergences of Ebola virus disease (EVD) without known contact.

173 s between deforestation and the emergence of Ebola virus disease (EVD), however, is still missing.

174 n the semen of men after their recovery from Ebola virus disease (EVD).

175 trol of virus replication, viremia and fatal Ebola virus disease (EVD).

176 eptide, that is produced in abundance during Ebola virus disease (EVD).

177 ance for use of post-exposure prophylaxis in Ebola virus disease and identify the priorities for futu

178 ul vaccination platform in a rodent model of Ebola virus disease and that GP1 N-glycan loss does not

179 Inadequate access to rapid testing for Ebola virus disease during the 2014-to-2016 outbreak led

180 ach indicator across three time periods: pre-Ebola virus disease epidemic (January, 2013, to February

181 nt of international responders, few cases of Ebola virus disease have been diagnosed in this group.

182 ested the effect of rVSV-ZEBOV in preventing Ebola virus disease in contacts and contacts of contacts

183 e primary analysis compared the incidence of Ebola virus disease in eligible and vaccinated individua

184 five species in the genus are known to cause Ebola Virus Disease in humans.

185 re we describe clinicopathologic features of Ebola virus disease in pregnancy.

186 py provided no benefit for the prevention of Ebola virus disease in rhesus macaques with regards to r

187 The massive outbreak of Ebola virus disease in west Africa between 2013 and 2016

188 Ebola virus disease is a serious illness of humans and n

189 rom all 117 clusters showed that no cases of Ebola virus disease occurred 10 days or more after rando

190 No cases of Ebola virus disease occurred 10 days or more after rando

191 No secondary cases of Ebola virus disease occurred among the vaccinees.

192 We sought to quantify the consequences of Ebola virus disease on maternal and child health service

193 indicators significantly declined during the Ebola virus disease outbreak in 2014.

194 The 2013-16 Ebola virus disease outbreak in west Africa was associat

195 In the post-Ebola virus disease outbreak period, vaccination coverag

196 Compared with pre-Ebola virus disease outbreak trends, significant decreas

197 d safely implemented at scale in response to Ebola virus disease outbreaks in rural settings.

198 sts a critical role for the delta peptide in Ebola virus disease pathology and as a possible target f

199 The 2014 west African epidemic of Ebola virus disease posed a major threat to the health s

200 Ebola virus disease poses a global health threat.

201 e causative agent of the largest outbreak of Ebola Virus Disease recorded.

202 In March, 2016, a flare-up of Ebola virus disease was reported in Guinea, and in respo

203 ugh August 2016, 256343 specimens tested for Ebola virus disease were captured in the database.

204 The rVSVDeltaG-ZEBOV-GP vaccine prevented Ebola virus disease when used at 2 x 107 plaque-forming

205 y outcome was a laboratory confirmed case of Ebola virus disease with onset 10 days or more from rand

206 es in the provision of care to patients with Ebola virus disease, including absence of pre-existing i

207 in Africa, Crimean-Congo haemorrhagic fever, Ebola virus disease, Lassa fever, and Marburg virus dise

208 After confirmation of a case of Ebola virus disease, we definitively enumerated on a lis

209 inform optimal care in a future outbreak of Ebola virus disease, we employed the Grading of Recommen

210 -ZEBOV offers substantial protection against Ebola virus disease, with no cases among vaccinated indi

211 at modulate the inflammatory response during Ebola virus disease.

212 dead bodies meeting the case definitions for Ebola virus disease.

213 cy of interferons (IFNs) in animal models of Ebola virus disease.

214 e) in the prevention of laboratory confirmed Ebola virus disease.

215 lowing the confirmation of the first case of Ebola virus disease.

216 hase 2 clinical development for treatment of Ebola virus disease.

217 ltaG-ZEBOV-GP vaccine in persons at risk for Ebola virus disease.

218 ated cytokine response that is a hallmark of Ebola virus disease.IMPORTANCE Understanding how the hos

219 Although the Ebola virus envelope glycoprotein (GP1,2) antagonizes th

220 recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine (rVSVDeltaG-ZE

221 recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine (rVSVG-ZEBOV-G

222 cination success.IMPORTANCE The West African Ebola virus epidemic was the largest to date, with more

223 rus throughout the region by analysing 1,610 Ebola virus genomes, which represent over 5% of the know

224 sent words of the human genome were found in Ebola virus genomes.

225 Based on the mutation rates for Ebola virus given its natural sequence evolution, these

226 Recent studies demonstrate that the Ebola virus glycoprotein (GP) acquired an A82V change du

227 ca, recombinant, infectious VSV encoding the Ebola virus glycoprotein effectively prevented virus-ass

228 We found that wild-type Ebola virus glycoprotein, in the context of this platfor

229 Ebola virus has been detected in the semen of men after

230 assessed the seroprevalence of antibodies to Ebola virus in a cross-sectional study of household cont

231 ells, the new device and protocol can detect Ebola virus in raw blood with clinically relevant sensit

232 wever, there is concern about persistence of Ebola virus in the reproductive tract of men who have su

233 unprecedented overseas intervention against Ebola virus in west Africa, dispatching 1200 workers, in

234 tissue damage in fatal EVD, and suggest that Ebola virus infection may induce aberrant neutrophils wh

235 bola virus-positive woman was diagnosed with Ebola virus infection on her first day of life.

236 or amplify proinflammatory signaling during Ebola virus infection, potentially contributing to the d

237 tic efficacy in a non-human primate model of Ebola virus infection.

238 asures for post-exposure prophylaxis against Ebola virus infection.

239 ca experienced an unanticipated explosion of Ebola virus infections.

240 prioritized this compound for testing in the Ebola virus intramuscular rhesus macaque challenge model

241 The frequency of asymptomatic infection with Ebola virus is unclear: previous estimates vary and ther

242 IFNs are weak inhibitors of Ebola virus Makona in these cell lines.

243 ombinant vesicular stomatitis virus encoding Ebola virus Makona variant GP1,2 (rVSV-MAK-GP) and obser

244 We studied cynomolgus macaques exposed to Ebola virus Makona via different routes with the intent

245 We found that the Ebola virus matrix protein, VP40, and envelope glycoprot

246 gram averaging to determine the structure of Ebola virus nucleocapsid within intact viruses and recom

247 tracellular trafficking of pathogens such as Ebola virus or bacterial toxins (e.g., cholera toxin).

248 The 2014 Zaire Ebola virus outbreak highlighted the need for a safe, ef

249 elucidate the determinants of host-specific Ebola virus pathogenicity.

250 In this study, we examined whether Ebola virus proteins affect BST2-mediated induction of N

251 ons, activated NF-kappaB in concert with the Ebola virus proteins at least as effectively as wild-typ

252 Activation of NF-kappaB by the Ebola virus proteins either alone or together with BST2

253 transcription factor NF-kappaB, responds to Ebola virus proteins.

254 Median duration of Ebola virus RNA detection was 158 days after onset (73-1

255 brary of short, terminally labeled probes to Ebola virus RNA followed by click assembly and analysis

256 d to improve amplification-free detection of Ebola virus RNA from blood.

257 ict that 50% and 90% of male survivors clear Ebola virus RNA from seminal fluid at 115 days (90% pred

258 INTERPRETATION: Time to clearance of Ebola virus RNA from seminal fluid varies greatly betwee

259 redicted that the number of men positive for Ebola virus RNA in affected countries would decrease fro

260 These data showed the long-term presence of Ebola virus RNA in semen and declining persistence with

261 nt over time, we found that concentration of Ebola virus RNA in semen during recovery is remarkably h

262 We report the presence of Ebola virus RNA in semen in a cohort of survivors of EVD

263 This study modeled the presence of Ebola virus RNA in the semen of male Ebola survivors par

264 stical modelling to describe the dynamics of Ebola virus RNA load in seminal fluid, including clearan

265 llow-up every 3-6 weeks, which we tested for Ebola virus RNA using quantitative real-time RT-PCR.

266 Ebola virus RNA was detected in 86 semen specimens from

267 Ebola virus RNA was detected in the semen of all 7 men w

268 by enhancing the hybridization of the target Ebola virus RNA with capture probes bound to the beads.

269 consistently found mutated in rodent-adapted Ebola virus strains.

270 ed 24 hours previously with a lethal dose of Ebola virus suppressed viral loads by more than 5 logs a

271 Understanding how the Ebola virus surface glycoprotein functions to facilitate

272 istribution generated by each system, spiked Ebola virus surrogates (MS2 and Phi6) into each system,

273 We evaluated the potential for Ebola virus surrogates to be aerosolized from three type

274 say reliably detected as few as 20 copies of Ebola virus templates in both human serum and saliva and

275 the dispersal, proliferation and decline of Ebola virus throughout the region by analysing 1,610 Ebo

276 The Ebola virus transmits a highly contagious, frequently fa

277 current overview of progress in the field of Ebola virus vaccine development.

278 ed by the Makona variant compared with other Ebola virus variants was lacking.

279 istinct oligomeric states of the Marburg and Ebola virus VP35 proteins may explain differences betwee

280 Although Ebola virus VP40 and GP both activate NF-kappaB independ

281 Testing for Ebola virus was done by real-time PCR and for malaria by

282 This Ebola virus was the Zaire strain of the virus family Fil

283 ive assay showed asymptomatic infection with Ebola virus was uncommon despite high exposure.

284 orresponding to 120 cDNA molecules of L-gene Ebola virus with a limit of detection of 33 cDNA molecul

285 spiratory syncytial virus, dengue virus, and Ebola virus, among others.

286 es, including dengue virus, West Nile virus, Ebola virus, Marburg virus, and Zika virus.

287 IFNs and, during the most recent outbreak of Ebola virus, questions regarding the suitability of the

288 sed mortality risk in patients infected with Ebola virus, supporting empirical malaria treatment in E

289 ults, MDMs treated with inactivated EBOV and Ebola virus-like particles (VLPs) induced NF-kappaB acti

290 A neonate born to an Ebola virus-positive woman was diagnosed with Ebola viru

291 d to have survived congenital infection with Ebola virus.

292 ranes in contrast to the matrix protein from Ebola virus.

293 parasites, either alone or concurrently with Ebola virus.

294 ies and emergent infectious diseases such as Ebola virus.

295 ependent of virion entrapment in the case of Ebola virus.

296 tigen detection of infections from Lassa and Ebola viruses (LASV and EBOV, respectively).

297 ptomatic disease caused by either Marburg or Ebola viruses in bats, spillover of these viruses into h

298 es seem to be required for the adaptation of Ebola viruses to a new species.

299 degree of sequence conservation among GP of Ebola viruses, it would be challenging to determine the

300 ssays currently in use in Liberia (including Ebola Zaire Target 1, major groove binder real-time-poly